23289-13-6

Upstream product

• 93114-14-8 N-benzyl-2-formylhydrazinecarbothioamide 
• 100-46-9 benzylamine 
• 622-78-6 Benzyl isothiocyanate 

Downstream Products

• 1448538-29-1 4-benzyl-3-(4-methylphenyl)-5-(phenylsulfanyl)-4H-1,2,4-triazole 
• 1001510-99-1 4-benzyl-3-(4-tert-butylphenyl)-5-(phenylsulfanyl)-4H-1,2,4-triazole 
• 1448538-30-4 4-benzyl-3-(3,5-dimethylphenyl)-5-(phenylsulfanyl)-4H-1,2,4-triazole 
• 1448538-31-5 4-benzyl-3-(4-fluorophenyl)-5-(phenylsulfanyl)-4H-1,2,4-triazole 
• 1448538-32-6 4-benzyl-3-(2-methoxyphenyl)-5-(phenylsulfanyl)-4H-1,2,4-triazole 
• 1448538-33-7 4-benzyl-3-(3-methoxyphenyl)-5-(phenylsulfanyl)-4H-1,2,4-triazole 
• 708245-91-4 4-benzyl-3-(4-methoxyphenyl)-5-(phenylsulfanyl)-4H-1,2,4-triazole 
• 1448538-34-8 2-[4-benzyl-5-(phenylsulfanyl)-4H-1,2,4-triazol-3-yl]aniline 
• 1448538-35-9 3-[4-benzyl-5-(phenylsulfanyl)-4H-1,2,4-triazol-3-yl]phenol 
• 440638-11-9 3-[4-benzyl-5-(phenylsulfanyl)-4H-1,2,4-triazol-3-yl]pyridine 
• 1448538-36-0 3-[4-benzyl-5-(phenylsulfanyl)-4H-1,2,4-triazol-3-yl]quinoline 
• 1448538-37-1 4-[4-benzyl-5-(phenylsulfanyl)-4H-1,2,4-triazol-3-yl]benzo-nitrile 
• 1448538-38-2 4-benzyl-3-benzylsulfanyl-5-((E)-styryl)-4H-[1,2,4]triazole 
• 1448538-39-3 4-benzyl-3-benzylsulfanyl-5-cyclohex-1-enyl-4H-[1,2,4]triazole 

Relevant academic research and scientific papers

Systematic structure-activity relationship (SAR) exploration of diarylmethane backbone and discovery of a highly potent novel uric acid transporter 1 (URAT1) inhibitor

In order to systematically explore and better understand the structure-activity relationship (SAR) of a diarylmethane backbone in the design of potent uric acid transporter 1 (URAT1) inhibitors, 33 compounds (1a-1x and 1ha-1hi) were designed and synthesized, and their in vitro URAT1 inhibitory activities (IC50) were determined. The three-round systematic SAR exploration led to the discovery of a highly potent novel URAT1 inhibitor, 1h, which was 200-and 8-fold more potent than parent lesinurad and benzbromarone, respectively (IC50 = 0.035 μM against human URAT1 for 1h vs. 7.18 μM and 0.28 μM for lesinurad and benzbromarone, respectively). Compound 1h is the most potent URAT1 inhibitor discovered in our laboratories so far and also comparable to the most potent ones currently under development in clinical trials. The present study demonstrates that the diarylmethane backbone represents a very promising molecular scaffold for the design of potent URAT1 inhibitors.

Synthesis of 5-substituted 3-mercapto-1,2,4-triazoles via Suzuki-Miyaura reaction

3-Bromo- and 3-iodo-N,S-dibenzyl-5-mercapto-1,2,4-triazoles were prepared and demonstrated as versatile building blocks for Suzuki-Miyaura cross-coupling with aryl, heteroaryl, and vinyl boronic acid derivatives. Deprotection of the resulting coupling products provided 5-substituted-3-mercapto-1,2,4-triazoles in good overall yields. This represents a novel and convenient approach for the introduction of a 3-mercapto-1,2,4-triazole substructure into target compounds.

Some Benzyl-Substituted Imidazoles, Triazoles, Tetrazoles, Pyridinethiones, and Structural Relatives as Multisubstrate Inhibitors of Dopamine β-Hydroxylase. 4. Structure-Activity Relationships at the Copper Binding Site

Structure-activity relationships (SAR) were determined for novel multisubstrate inhibitors of dopamine β-hydroxylase (DBH; EC 1.14.17.1) by examining the effects upon in vitro inhibitory potencies resulting from structural changes at the copper-binding region of inhibitor.Attempts were made to determine replacement groups for the thione sulfur atom of the prototypical inhibitor 1-(4-hydroxybenzyl)imidazole-2-thione described previously.The synthesis and evaluation of oxygen and nitrogen analogues of the soft thione group demonstrated the sulfur atom to be necessary for optimal activity.An additional series of imidazole-2-thione relatives was prepared in an effort to probe the relationship between the pKa of the ligand group and inhibitor potency.In vitro inhibitory potency was shown not to correlate with ligand pKa over a range of approximately 10 pKa units, and a rationale for this is advanced.Additional ligand modifications were prepared in order to explore bulk tolerance at the enzyme oxygen binding site and to determine the effects of substituting a six-membered ligand group for the five-membered imidazole-2-thione ligand.

Dopamine-β-hydroxylase inhibitors

Potent dopamine-β-hydroxylase inhibitors having the Formula STR1 that are useful to inhibit dopamine-β-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-β-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.